What is the Artemis MRI/ TRUS Fusion Prostate Biopsy solution?
TRUS stands for Transrectal Ultrasonography. It is a medium for capturing and creating the outlook image of the prostate gland with the help of ultrasound procedures.
The Artemis MRI/TRUS Fusion is a revolutionary imaging and 3D navigation system that provides a complete prostate biopsy management platform. The system allows the doctors to take images from the MRI and use them in conjunction with a standard ultrasound guided biopsy. The system uses robotic principles to mimic a doctors arm movements. This system increases the accuracy, robustness and reliability of performing a MRI/US Fusion Targeted Biopsy.
TRUS is suggested by doctors when they suspect a prostate cancer based on an abnormal DRE (Digital Rectal Examination), or increased PSA (Prostate-Specific Antigen), and other imaging techniques. TRUS is costly, and it rarely detects prostate cancer that DRE or PSA cannot find. As an outcome, TRUS is widely taken help for guiding a biopsy, but for routine screening, it is not recommendable.
How does it help?
An accurate prostate tumour diagnosis and appropriate treatment depend on the ability to efficiently perform the biopsy on specific areas of the prostate. By fusing the MRI and live ultrasound images, the doctors at Medanta can more effectively perform a targeted biopsy of select tissue. The biopsy results then lead to a more accurate diagnosis along with better information to help you make a smarter, more individualised choice about your treatment.